314 related articles for article (PubMed ID: 16919519)
1. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Bays H
Am J Cardiol; 2006 Aug; 98(4A):71i-76i. PubMed ID: 16919519
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
3. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Rupp H
Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
[TBL] [Abstract][Full Text] [Related]
4. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
5. Omacor and omega-3 fatty acids for treatment of coronary artery disease and the pleiotropic effects.
Kar S
Am J Ther; 2014; 21(1):56-66. PubMed ID: 21975796
[TBL] [Abstract][Full Text] [Related]
6. Omega-3 polyunsaturated fatty acids (Omacor) for hypertriglyceridemia.
Med Lett Drugs Ther; 2005 Nov; 47(1221):91. PubMed ID: 16267495
[No Abstract] [Full Text] [Related]
7. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
Ryan AS; Keske MA; Hoffman JP; Nelson EB
Am J Ther; 2009; 16(2):183-92. PubMed ID: 19145206
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of omega-3 fatty acids in children and adults with IgA nephropathy is dosage- and size-dependent.
Hogg RJ; Fitzgibbons L; Atkins C; Nardelli N; Bay RC;
Clin J Am Soc Nephrol; 2006 Nov; 1(6):1167-72. PubMed ID: 17699343
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of Omacor in severe hypertriglyceridemia.
Harris WS; Ginsberg HN; Arunakul N; Shachter NS; Windsor SL; Adams M; Berglund L; Osmundsen K
J Cardiovasc Risk; 1997; 4(5-6):385-91. PubMed ID: 9865671
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with statins and omega-3 fatty acids.
Nambi V; Ballantyne CM
Am J Cardiol; 2006 Aug; 98(4A):34i-38i. PubMed ID: 16919515
[TBL] [Abstract][Full Text] [Related]
11. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
12. Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Donadio JV; Bergstralh EJ; Bibus DM; Grande JP
Clin J Am Soc Nephrol; 2006 Sep; 1(5):933-9. PubMed ID: 17699310
[TBL] [Abstract][Full Text] [Related]
13. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides.
Sadovsky R; Kris-Etherton P
Postgrad Med; 2009 Jul; 121(4):145-53. PubMed ID: 19641280
[TBL] [Abstract][Full Text] [Related]
14. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
Davidson MH; Phillips AK; Kling D; Maki KC
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1045-54. PubMed ID: 25089906
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Ethyl-Ester Omega-3 Fatty Acid in Taiwanese Hypertriglyceridemic Patients.
Su TC; Hwang JJ; Huang KC; Chiang FT; Chien KL; Wang KY; Charng MJ; Tsai WC; Lin LY; Vige R; Olivar JE; Tseng CD
J Atheroscler Thromb; 2017 Mar; 24(3):275-289. PubMed ID: 27600795
[TBL] [Abstract][Full Text] [Related]
16. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia.
Backes J; Anzalone D; Hilleman D; Catini J
Lipids Health Dis; 2016 Jul; 15(1):118. PubMed ID: 27444154
[TBL] [Abstract][Full Text] [Related]
17. Omacor effects on serum lipids and clinical outcome.
Ito MK; Marrs J; Williams C
Am J Cardiol; 2007 Jan; 99(1):145. PubMed ID: 17196478
[No Abstract] [Full Text] [Related]
18. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Nordøy A
Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
[TBL] [Abstract][Full Text] [Related]
19. The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.
Stalenhoef AF; de Graaf J; Wittekoek ME; Bredie SJ; Demacker PN; Kastelein JJ
Atherosclerosis; 2000 Nov; 153(1):129-38. PubMed ID: 11058707
[TBL] [Abstract][Full Text] [Related]
20. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides.
Kedia AW; Lynch E
Postgrad Med; 2015; 127(8):869-73. PubMed ID: 26453247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
